Emerging opportunities in the viral vector manufacturing market include personalized medicine growth, expanded clinical trials, and regional manufacturing partnerships. Advances in bioprocessing and ...
Therapeutics Co. Ltd. ( ($HK:2126) ) has issued an announcement. JW Therapeutics announced that the National Medical Products ...
OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s ...
Cell and gene therapy outfit Oxford Biomedica said on Tuesday that it had agreed to acquire a viral vector manufacturing site ...
FA is an inherited syndrome that impairs the body's chromosomal repair systems, causing the bone marrow to lose its ability ...
IB [email protected] ReiThera to Showcase Innovative Viral Vector Platforms at ESGCT 2025Rome, Italy – September 30 2025 – ReiThera Srl, the Italian leading Contract Development ...
Thermo Fisher Scientific Inc., the world leader in serving science, today announced that Dr. Park, an emerging viral vector contract development and manufacturing organization (CDMO) based in South ...
First commercially available cell culture solution for HEK293 cells and perfusion -– optimized for high cell density (HCD), intensified processes and perfusion cultures Additional capabilities for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback